Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8
CD8+ T cells
FLT3
MERTK
T lymphocytes
receptor tyrosine kinases
small molecule inhibitors
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
08 Nov 2021
08 Nov 2021
Historique:
received:
28
09
2021
revised:
04
11
2021
accepted:
05
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
There is an increasing interest in the development of Receptor Tyrosine Kinases inhibitors (RTKIs) for cancer treatment, as dysregulation of RTK expression can govern oncogenesis. Among the newer generations of RTKIs, many target Mer Tyrosine Kinase (MERTK) and Fms related RTK 3 (FLT3). Next to being overexpressed in many cancers, MERTK and FLT3 have important roles in immune cell development and function. In this study, we address how the new generation and potent RTKIs of MERTK/FLT3 affect human primary CD8
Identifiants
pubmed: 34835225
pii: vaccines9111294
doi: 10.3390/vaccines9111294
pmc: PMC8617686
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Danish Council for Independent Research
ID : DFF-1331-00095B
Organisme : Danish Cancer Society
ID : R72-A4396-13-S2
Organisme : European Union
ID : H2020 grant no. 641549
Références
Oncogene. 2013 Nov 14;32(46):5359-68
pubmed: 23474756
J Med Chem. 2014 Aug 28;57(16):7031-41
pubmed: 25068800
Nature. 2001 May 10;411(6834):207-11
pubmed: 11346799
Cell. 1991 Jun 28;65(7):1143-52
pubmed: 1648448
Nat Immunol. 2013 Mar;14(3):262-70
pubmed: 23377202
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385715
J Clin Oncol. 2013 Oct 10;31(29):3681-7
pubmed: 24002496
Mol Cancer Ther. 2013 Apr;12(4):438-47
pubmed: 23412931
J Immunol. 2010 Jan 15;184(2):685-93
pubmed: 20018615
Blood. 2002 Sep 1;100(5):1532-42
pubmed: 12176867
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32244867
Blood. 2012 Nov 8;120(19):4049-57
pubmed: 22990016
Cancer Immunol Res. 2019 Sep;7(9):1472-1484
pubmed: 31266785
Neuro Oncol. 2018 Jan 10;20(1):92-102
pubmed: 28605477
Exp Hematol. 2008 Oct;36(10):1297-308
pubmed: 18619726
Mol Cancer Res. 2011 Jun;9(6):801-12
pubmed: 21521745
Mol Cancer. 2013 Mar 07;12:19
pubmed: 23497317
JCI Insight. 2016 Mar;1(3):e85630
pubmed: 27158668
Blood. 2011 Mar 24;117(12):3286-93
pubmed: 21263155
Mol Cancer Ther. 2015 Sep;14(9):2014-22
pubmed: 26162689
Haematologica. 2014 Jun;99(6):e90-3
pubmed: 24633870
Semin Immunol. 2007 Jun;19(3):162-72
pubmed: 17383196
Clin Cancer Res. 2019 Dec 15;25(24):7576-7584
pubmed: 31540976
Mol Cancer Ther. 2019 Feb;18(2):278-288
pubmed: 30482852
Cancer Immunol Res. 2014 Jan;2(1):70-9
pubmed: 24416731
Front Immunol. 2020 Sep 25;11:564133
pubmed: 33101282
Nat Rev Cancer. 2014 Dec;14(12):769-85
pubmed: 25568918
J Exp Med. 2009 Dec 21;206(13):3115-30
pubmed: 20008528
Immunity. 2020 Feb 18;52(2):357-373.e9
pubmed: 32049051
Blood. 2001 Feb 15;97(4):1027-34
pubmed: 11159533
PLoS One. 2016 Oct 26;11(10):e0165107
pubmed: 27783662
Front Immunol. 2019 Mar 15;10:468
pubmed: 30930902
Am J Hematol. 2018 Feb;93(2):222-231
pubmed: 29090473
Blood. 2009 Oct 1;114(14):2984-92
pubmed: 19654408
Blood. 2008 Feb 1;111(3):1366-77
pubmed: 17962511
Haematologica. 2017 Aug;102(8):1378-1389
pubmed: 28522571
Cell. 2007 Dec 14;131(6):1124-36
pubmed: 18083102
Syst Rev. 2020 Dec 7;9(1):285
pubmed: 33287892
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13091-6
pubmed: 23878224
Eur J Immunol. 1996 Jul;26(7):1504-10
pubmed: 8766553
Cancer Res. 2019 Apr 15;79(8):1996-2008
pubmed: 30723115
Mol Cancer. 2018 Feb 19;17(1):58
pubmed: 29455648
Oncotarget. 2017 Sep 16;8(55):93785-93799
pubmed: 29212189
J Leukoc Biol. 2015 Apr;97(4):751-60
pubmed: 25624460
Cancer Lett. 2013 Feb 1;329(1):45-58
pubmed: 23036488
Nat Immunol. 2008 Jun;9(6):676-83
pubmed: 18469816
Clin Cancer Res. 2017 Mar 15;23(6):1481-1492
pubmed: 27649555
Blood. 1996 Feb 1;87(3):1089-96
pubmed: 8562934
Cancer Res. 2019 May 15;79(10):2669-2683
pubmed: 30877108